Alnylam Pharmaceuticals, Inc. (ALNY) quarterly cash flow statement — complete operating, investing & financing history
| Cash from Operations | 70.5M | 163.56M | 325.11M | 153.73M | -118.31M | -94.66M | 43.71M | 124.16M | -81.52M | -29.8M | 359.41M | -58.99M |
| Operating CF Margin % | 6.04% | 14.91% | 26.03% | 19.87% | -19.91% | -15.96% | 8.73% | 18.82% | -16.49% | -6.78% | 47.89% | -18.51% |
| Operating CF Growth % | 159.59% | 272.78% | 643.84% | 23.82% | -45.14% | -217.71% | -87.84% | 310.49% | 51.03% | 77.42% | 411.76% | 51.97% |
| Net Income | 205.99M | 186.42M | 251.08M | -66.28M | -57.48M | -83.76M | -111.57M | -16.89M | -65.94M | -137.87M | 147.75M | -276.02M |
| Depreciation & Amortization | 13.55M | 13.51M | 13.8M | 13.94M | 14.4M | -20.55M | 48.7M | 15M | 13.52M | 13.48M | 23.53M | 23.45M |
| Stock-Based Compensation | 70.15M | 0 | 108.21M | 111.68M | 56.71M | 91.64M | 45.8M | 89.29M | 45.35M | 41.99M | 63.94M | 75.8M |
| Deferred Taxes | 9.31M | -27.17M | 5.6M | 9.73M | 9.64M | 0 | 0 | 0 | 454K | -53.1M | 39.26M | 28.82M |
| Other Non-Cash Items | 53.19M | 63.95M | 151.07M | 34.57M | 75.45M | -7.79M | 30.05M | 86.06M | 46.4M | 98.91M | 59.41M | 24.4M |
| Working Capital Changes | -281.7M | -73.15M | -204.66M | 50.08M | -217.05M | -74.21M | 30.73M | -49.3M | -121.3M | 6.79M | 25.53M | 64.58M |
| Change in Receivables | -110.42M | 184.25M | -399.86M | -136.91M | -7.43M | -59.51M | -37.09M | 9.64M | 410K | 3.87M | -107.99M | -2.97M |
| Change in Inventory | -3.32M | -13.86M | 4.98M | 11.14M | 6.21M | 849K | 5.92M | 6.79M | 22K | 11.99M | 4.79M | 1.99M |
| Change in Payables | -176.03M | 0 | 223.51M | 182.15M | -155.74M | -62.11M | 83.59M | 74.47M | -4.87M | -38.67M | 118.74M | 82.74M |
| Cash from Investing | -25.54M | -37.17M | 501.11M | -141.38M | 113.77M | -52.91M | -30.25M | 33.94M | -67.62M | -240.66M | -10.76M | -8.71M |
| Capital Expenditures | -21.83M | -23.29M | -12.14M | -14.29M | -8.97M | -9.09M | -4.19M | -8.02M | -12.97M | -15.31M | -17.09M | -15.92M |
| CapEx % of Revenue | 1.87% | 2.12% | 0.97% | 1.85% | 1.51% | 1.53% | 0.84% | 1.22% | 2.62% | 3.48% | 2.28% | 4.99% |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 225.35M | -10.77M | -7.21M |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -4.1M | 0 | -450K | 9.25M | 48.83M | -117K | 0 | 0 | 0 | -225.35M | 6.33M | 7.21M |
| Cash from Financing | 15.71M | 45.32M | -448.35M | 53.76M | 44.08M | 31M | 102.75M | 131.5M | 28.91M | 39.23M | 33.14M | 53.39M |
| Debt Issued (Net) | 2.57M | -61.21M | -494.01M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 13.16M | 41.7M | -130.59M | 81.22M | 49.37M | 36.28M | 108.04M | 132.78M | 25.86M | 30.89M | 24.8M | 49.39M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -9K | 64.82M | 176.25M | -27.46M | -5.28M | -5.28M | -5.28M | -1.28M | 3.05M | 8.33M | 8.33M | 4M |
| Net Change in Cash | 53.61M | 166M | 376.94M | 93.61M | 53.6M | -133.85M | 131.31M | 286.61M | -130.81M | -220.34M | 375.23M | -14.44M |
| Free Cash Flow | 48.67M | 140.26M | 312.97M | 139.44M | -127.28M | -103.76M | 39.52M | 116.14M | -94.49M | -45.1M | 342.32M | -74.91M |
| FCF Margin % | 4.17% | 12.79% | 25.06% | 18.02% | -21.42% | -17.49% | 7.89% | 17.6% | -19.11% | -10.26% | 45.61% | -23.5% |
| FCF Growth % | 138.24% | 235.19% | 692.02% | 20.06% | -34.71% | -130.04% | -88.46% | 255.05% | 47.61% | 70.64% | 359.74% | 46.06% |
| FCF per Share | 0.35 | 1.03 | 2.28 | 1.08 | -0.98 | -0.81 | 0.31 | 0.92 | -0.75 | -0.36 | 2.61 | -0.60 |
| FCF Conversion (FCF/Net Income) | 0.34x | 0.88x | 1.29x | -2.32x | 2.06x | 1.13x | -0.39x | -7.35x | 1.24x | 0.22x | 2.43x | 0.21x |
| Interest Paid | 64.2M | 113.32M | 23.89M | 14.56M | 66.93M | 12.33M | 0 | 0 | 30.95M | 0 | 0 | 0 |
| Taxes Paid | 2.37M | 0 | 1.28M | -1.87M | 2.97M | 0 | 0 | 0 | 1.99M | 0 | 0 | 0 |